BioSpace News Archive

Selva Therapeutics, Inc. (“Selva”) announced new preclinical data demonstrating SLV213, when given as a prophylactic or a treatment for SARS-CoV-2 infection, protects against SARS-CoV-2-induced diffuse alveolar damage (DAD), which is associated with the early stages of acute respiratory distress syndrome (ARDS).

Anika Therapeutics, Inc. today announced that the Company plans to issue its second quarter 2021 financial results after the close of the market on Thursday, August 5, 2021 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final results from the Phase 2 ANT-005 study with its novel investigational anticoagulant abelacimab

The American Pharmacists Association Foundation (APhA Foundation) and NOWDiagnostics, Inc., a Springdale-based leader in innovative diagnostics testing, today announced that NOWDiagnostics’ ADEXUSDx® COVID-19 antibody test, a rapid-results self-contained fingerstick test,

BioMarin Pharmaceutical Inc. today announced new data for valoctocogene roxaparvovec in its positive pivotal study, GENEr8-1, during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2021 of $1.06 per share on the company’s common stock.

The Government of Canada is prioritizing the health and safety of everyone in Canada by taking a risk-based and measured approach to re-opening our borders.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company’s Board of Directors

Atreca, Inc. (Atreca) (NASDAQ: BCEL), today announced the appointment of Dr. Stacey Ma, Executive Vice President and Head of Technical Operations at Sana Biotechnology, and Stephen R. Brady, Chief Executive Officer of Tempest Therapeutics, to its Board of Directors.